



## Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn's and Colitis Organisation

January 8, 2024

### Six Presentations Highlight Landos' Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative Colitis

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos" or the "Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that six abstracts were accepted for poster presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation (ECCO). The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69. The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.

"Immunometabolic targets work to restrict entry into the inflammatory cascade to restore and maintain homeostasis and are poised to be the next frontier in treating autoimmune diseases. We are excited to present data from multiple studies including the impact of NX-13 on eosinophil infiltration and visceral hypersensitivity, as well as confirming its relevancy in multiple models and species. Additionally, we are pleased to share new preclinical insights into the potential role of PLXDC2 in ulcerative colitis," said Fabio Cataldi, M.D., Executive Vice-President & Chief Medical Officer at Landos. "The broad range of innovative research by our scientists and esteemed collaborators underscores our commitment to leveraging immunometabolism to create safer and more effective treatments for inflammatory bowel diseases, particularly in ulcerative colitis."

Landos has two novel targets anchoring libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications, including the clinical stage program NX-13 for ulcerative colitis (UC).

#### Presentation Details

All six posters will be presented as part of the guided poster session taking place on Friday, February 23, 2024 from 12:40-13:40 CEST at Poster Exhibition Hall A.

**Title:** The Immunometabolic Bimodal Mechanism of NLRX1 Agonist NX-13 in a Pig Model of Ulcerative Colitis

**Presenter:** Prof. Bram Verstockt, M.D., PhD; University Hospitals Leuven and KU Leuven, Leuven, Belgium

**Poster number:** P077

**Title:** Identification of a Novel Immunometabolic Target and Agonist for PLXDC2 for Amelioration of DSS Colitis Model in Mice

**Presenter:** Prof. Bram Verstockt, M.D., PhD; University Hospitals Leuven and KU Leuven, Leuven, Belgium

**Poster number:** P086

**Title:** Role of NLRX1 Agonist NX-13 in Reducing Visceral Hypersensitivity in Preclinical Gastrointestinal Inflammation

**Presenter:** Prof. Bram Verstockt, M.D., PhD; University Hospitals Leuven and KU Leuven, Leuven, Belgium

**Poster number:** P114

**Title:** Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases

**Presenter:** Prof. Silvio Danese, M.D., PhD; IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University

**Poster number:** P144

**Title:** The Effect of NLRX1 Activation on Eosinophils in Ulcerative Colitis and Inflammation: Translational Learnings Across Diseases and from Mouse to Human

**Presenter:** Prof. Bram Verstockt, M.D., PhD; University Hospitals Leuven and KU Leuven, Leuven, Belgium

**Poster number:** P571

**Title:** Translating Pharmacokinetic and Efficacy Outcomes of NLRX1 Agonist NX-13: Contrasting a Pig Model and a Human Phase 1b Clinical Trial in Ulcerative Colitis

**Presenter:** Prof. Britta Siegmund, M.D., PhD; Charité – Universitätsmedizin, Berlin

**Poster number:** P739

NX-13 is currently in a Phase 2 proof-of-concept trial (NEXUS: [NCT05785715](#)) to evaluate the safety, efficacy and pharmacokinetics in patients with moderate to severe UC. The Company expects to report topline results in the fourth quarter of 2024.

#### About Landos Biopharma

Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease. Our mission is to create safer and more effective oral treatments that address the therapeutic gap in the current treatment paradigm.

We have a portfolio of novel targets anchoring two libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space.

We are currently focused on advancing the clinical development of NX-13 in UC. We initiated the NEXUS Phase 2 proof-of-concept trial in April 2023 and expect to report topline results in the fourth quarter of 2024.

For more information, please visit [www.landosbiopharma.com](http://www.landosbiopharma.com).

### **Cautionary Note on Forward-Looking Statements**

Statements in this press release about future expectations, plans and prospects for Landos Biopharma, Inc. (the "Company"), including statements about the Company's strategy, clinical development and regulatory plans for its product candidates and other statements containing the words "anticipate", "plan", "expect", "may", "will", "could", "believe", "look forward", "potential", the negatives thereof, variations thereon and similar expressions, or any discussions of strategy constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of current and future clinical trials, including the ongoing Phase 2 trial of NX-13, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates, our anticipated cash runway and other similar risks. Risks regarding the Company's business are described in detail in its Securities and Exchange Commission ("SEC") filings, including in its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the SEC's website at [www.sec.gov](http://www.sec.gov). Additional information will be made available in other filings that the Company makes from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

### **Contacts**

Rebecca Mosig, Vice President, Corporate Development  
Landos Biopharma  
[ir@landosbiopharma.com](mailto:ir@landosbiopharma.com)

Mike Moyer  
LifeSci Advisors, LLC  
[mmoyer@lifesciadvisors.com](mailto:mmoyer@lifesciadvisors.com)